Cargando…

Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer

We previously reported that patients with a clinical complete response (CR) following radiofrequency thermal treatment exhibit significantly increased body temperature compared with other groups, whereas patients with a clinical partial response or stable disease depended on the absence or presence...

Descripción completa

Detalles Bibliográficos
Autores principales: SHOJI, HISANORI, MOTEGI, MASAHIKO, OSAWA, KIYOTAKA, OKONOGI, NORIYUKI, OKAZAKI, ATSUSHI, ANDOU, YOSHITAKA, ASAO, TAKAYUKI, KUWANO, HIROYUKI, TAKAHASHI, TAKEO, OGOSHI, KYOJI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811390/
https://www.ncbi.nlm.nih.gov/pubmed/26985914
http://dx.doi.org/10.3892/or.2016.4659
_version_ 1782423944729460736
author SHOJI, HISANORI
MOTEGI, MASAHIKO
OSAWA, KIYOTAKA
OKONOGI, NORIYUKI
OKAZAKI, ATSUSHI
ANDOU, YOSHITAKA
ASAO, TAKAYUKI
KUWANO, HIROYUKI
TAKAHASHI, TAKEO
OGOSHI, KYOJI
author_facet SHOJI, HISANORI
MOTEGI, MASAHIKO
OSAWA, KIYOTAKA
OKONOGI, NORIYUKI
OKAZAKI, ATSUSHI
ANDOU, YOSHITAKA
ASAO, TAKAYUKI
KUWANO, HIROYUKI
TAKAHASHI, TAKEO
OGOSHI, KYOJI
author_sort SHOJI, HISANORI
collection PubMed
description We previously reported that patients with a clinical complete response (CR) following radiofrequency thermal treatment exhibit significantly increased body temperature compared with other groups, whereas patients with a clinical partial response or stable disease depended on the absence or presence of output limiting symptoms. The aim of this study was to evaluate the correlation among treatment response, Hidaka radiofrequency (RF) output classification (HROC: termed by us) and changes in body temperature. From December 2011 to January 2014, 51 consecutive rectal cancer cases were included in this study. All patients underwent 5 RF thermal treatments with concurrent chemoradiation. Patients were classified into three groups based on HROC: with ≤9, 10–16, and ≥17 points, calculated as the sum total points of five treatments. Thirty-three patients received surgery 8 weeks after treatment, and among them, 32 resected specimens were evaluated for histological response. Eighteen patients did not undergo surgery, five because of progressive disease (PD) and 13 refused because of permanent colostomy. We demonstrated that good local control (ypCR + CR + CRPD) was observed in 32.7% of cases in this study. Pathological complete response (ypCR) was observed in 15.7% of the total 51 patients and in 24.2% of the 33 patients who underwent surgery. All ypCR cases had ≥10 points in the HROC, but there were no patients with ypCR among those with ≤9 points in the HROC. Standardization of RF thermal treatment was performed safely, and two types of patients were identified: those without or with increased temperatures, who consequently showed no or some benefit, respectively, for similar RF output thermal treatment. We propose that the HROC is beneficial for evaluating the efficacy of RF thermal treatment with chemoradiation for rectal cancer, and the thermoregulation control mechanism in individual patients may be pivotal in predicting the response to RF thermal treatment.
format Online
Article
Text
id pubmed-4811390
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-48113902016-04-06 Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer SHOJI, HISANORI MOTEGI, MASAHIKO OSAWA, KIYOTAKA OKONOGI, NORIYUKI OKAZAKI, ATSUSHI ANDOU, YOSHITAKA ASAO, TAKAYUKI KUWANO, HIROYUKI TAKAHASHI, TAKEO OGOSHI, KYOJI Oncol Rep Articles We previously reported that patients with a clinical complete response (CR) following radiofrequency thermal treatment exhibit significantly increased body temperature compared with other groups, whereas patients with a clinical partial response or stable disease depended on the absence or presence of output limiting symptoms. The aim of this study was to evaluate the correlation among treatment response, Hidaka radiofrequency (RF) output classification (HROC: termed by us) and changes in body temperature. From December 2011 to January 2014, 51 consecutive rectal cancer cases were included in this study. All patients underwent 5 RF thermal treatments with concurrent chemoradiation. Patients were classified into three groups based on HROC: with ≤9, 10–16, and ≥17 points, calculated as the sum total points of five treatments. Thirty-three patients received surgery 8 weeks after treatment, and among them, 32 resected specimens were evaluated for histological response. Eighteen patients did not undergo surgery, five because of progressive disease (PD) and 13 refused because of permanent colostomy. We demonstrated that good local control (ypCR + CR + CRPD) was observed in 32.7% of cases in this study. Pathological complete response (ypCR) was observed in 15.7% of the total 51 patients and in 24.2% of the 33 patients who underwent surgery. All ypCR cases had ≥10 points in the HROC, but there were no patients with ypCR among those with ≤9 points in the HROC. Standardization of RF thermal treatment was performed safely, and two types of patients were identified: those without or with increased temperatures, who consequently showed no or some benefit, respectively, for similar RF output thermal treatment. We propose that the HROC is beneficial for evaluating the efficacy of RF thermal treatment with chemoradiation for rectal cancer, and the thermoregulation control mechanism in individual patients may be pivotal in predicting the response to RF thermal treatment. D.A. Spandidos 2016-05 2016-03-07 /pmc/articles/PMC4811390/ /pubmed/26985914 http://dx.doi.org/10.3892/or.2016.4659 Text en Copyright: © Shoji et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
SHOJI, HISANORI
MOTEGI, MASAHIKO
OSAWA, KIYOTAKA
OKONOGI, NORIYUKI
OKAZAKI, ATSUSHI
ANDOU, YOSHITAKA
ASAO, TAKAYUKI
KUWANO, HIROYUKI
TAKAHASHI, TAKEO
OGOSHI, KYOJI
Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
title Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
title_full Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
title_fullStr Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
title_full_unstemmed Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
title_short Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
title_sort radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811390/
https://www.ncbi.nlm.nih.gov/pubmed/26985914
http://dx.doi.org/10.3892/or.2016.4659
work_keys_str_mv AT shojihisanori radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT motegimasahiko radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT osawakiyotaka radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT okonoginoriyuki radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT okazakiatsushi radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT andouyoshitaka radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT asaotakayuki radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT kuwanohiroyuki radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT takahashitakeo radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer
AT ogoshikyoji radiofrequencythermaltreatmentwithchemoradiotherapyforadvancedrectalcancer